Results 201 to 210 of about 3,046,243 (224)

Essential thrombocythemia treatment algorithm 2018

Blood Cancer Journal, 2018
Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median
Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia

Platelets, 2020
Essential thrombocythemia (ET) is characterized by persistently elevated platelet counts and an increased risk of thromboembolic events. Dysregulated expression of small noncoding microRNAs (miRNAs) have been shown in ET and may influence platelet ...
Jenny Q D Tran, O. H. Pedersen, M. Larsen, E. Grove, S. Kristensen, A. Hvas, P. Nissen   +6 more
semanticscholar   +1 more source

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

European Journal of Haematology, 2020
In patients with essential thrombocythemia (ET), after the JAK2V617F driver mutation, mutations in CALR are common (classified as type 1, 52‐bp deletion or type 2, 5‐bp insertion).
M. P. Pérez Encinas, M. Sobas, M. Gómez-Casares, Aitor Abuín Blanco, María Soledad Noya Pereira, J. Raya, M. Andrade-Campos, A. Álvarez Larrán, K. Lewandowski, Szukalski Łukasz, J. C. Hernández Boluda, F. Ferrer-Marín, M. Fox, A. Gołos, M. Gasior Kabat, E. Magro Mazo, A. Czyż, Alejandro Martín Martín, Beatriz Bellosillo Paricio, C. Quinteiro García, J. G. González Martín, R. Stuckey   +21 more
semanticscholar   +1 more source

Essential Thrombocythemia: A Review.

Journal of the American Medical Association (JAMA)
Importance Essential thrombocythemia, a clonal myeloproliferative neoplasm with excessive platelet production, is associated with an increased risk of thrombosis and bleeding.
A. Tefferi, N. Gangat, G. G. Loscocco, P. Guglielmelli, N. Szuber, A. Pardanani, A. Orazi, T. Barbui, A. Vannucchi   +8 more
semanticscholar   +1 more source

Essential Thrombocythemia.

New England Journal of Medicine, 2019
Abnormal blood clotting (thrombosis) is common in people with essential thrombocythemia and causes many signs and symptoms of this condition. Clots that block blood flow to the brain can cause strokes or temporary stroke-like episodes known as transient ...
A. Tefferi, A. Pardanani
semanticscholar   +1 more source

Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia

Current Hematologic Malignancy Reports, 2022
I. Krečak, M. Lucijanić, S. Verstovsek
semanticscholar   +1 more source

Essential Thrombocythemia

The Journal for Nurse Practitioners, 2023
R. Foreman, Richard Brzustowicz
semanticscholar   +1 more source

Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera

International journal of hematology, 2020
I. Krečak, H. Holik, M. Martina, I. Zekanović, B. Coha, V. Gverić-Krečak   +5 more
semanticscholar   +1 more source

Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis

Annals of Hematology, 2020
A. Álvarez-Larrán, Arturo Pereira, M. Magaz, J. Hernández-Boluda, M. Garrote, B. Cuevas, F. Ferrer-Marín, M. Gómez-Casares, V. García‐Gutiérrez, M. Mata-Vázquez, F. Turon, V. Hernández-Gea, E. Arellano-Rodrigo, F. Cervantes, J. García‐Pagán, on behalf of the French Jdrf Diabetic Nephropathy Col groups   +15 more
semanticscholar   +1 more source

Advances in Understanding and Management of Myeloproliferative Neoplasms

Ca-A Cancer Journal for Clinicians, 2009
Paola Guglielmelli
exaly